Two of the reasons why glioblastoma multiforme (GBM) has proven one of the toughest cancers in oncology – being incurable, invariably fatal and with a median overall survival (OS) of two years or less – are its heterogeneity in terms of antigen expression and the difficulty of getting drugs across the blood-brain barrier. But Mustang Bio Inc.’s CAR-T cell therapy MB-101 has managed to get past both hurdles to achieve a significant improvement in OS among patients with recurrent GBM.
Mustang Bio’s MB-101 Gallops To Win In Glioblastoma
The lead author on the Phase I study told Scrip that in addition to targeting a widely expressed antigen on GBM tumors, the CAR-T also stimulates the body’s immune system.
More from Immuno-oncology
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
• By
Sun is acquiring Checkpoint Therapeutics, opening up opportunities to build out its strategy in the onco-derm segment with the US firm’s FDA-approved anti-PD-L1 mAb.
More from Anticancer
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.